Panosome
Heidelberg
About Panosome
Panosome is making the most challenging target classes such as carbohydrates, peptides and small molecules addressable to antibodies. Spun out of the German Cancer Research Center in 2020, Panosome is using the revolutionary VAST technology to address antibody targets in several indications, ranging from cancer to autoimmune diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $5.4M
- Funding stage: Seed
- Last round: Seed (Jun 2024)
- Website: panosome.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/panosome-137691 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.